Dimensional Analysis of CD44High CD24Low and Ki67 in Triple Negative Breast Cancer

Authors

  • Betty Tan Department of Anatomic Pathology of Medical Faculty, University of Sumatera Utara, Jl. Dr Mansyur No 5, Medan 20155, Indonesia
  • Mpu Kanoko Department of Anatomic Pathology of Medical Faculty, University of Indonesia, Jakarta, Indonesia
  • Gino Tan Department of Clinical Pathology of Medical Faculty, University of Sumatera Utara, Medan, Indonesia
  • Adang Bachtiar Faculty of Public Health, University of Indonesia, Jakarta, Indonesia
  • Delfitri Munir Department of Otorhinolaryngology of Medical Faculty, University of Sumatera Utara, Medan, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2019.182

Keywords:

Triple-negative breast cancer, Stemness, Differentiation, EMT, CD44, CD24

Abstract

AIM: To study the dimensional analysis CD44high CD24low and Ki67 in triple negative breast cancer (TNBC).

METHODS: This cross-sectional study was performed on patients with breast cancer in Haji Adam Malik Hospital Medan from 2013 to 2016 to determine the frequency and pathologic features of TNBC by immunohistochemistry stained.

RESULTS: By using immunohistochemistry staining panel of CD44, CD24, Twist, Claudin 7, CK5, CK8/18, EMA, E-Cadherin, Ki-67, a total 67 breast tumour samples with TNBC were classified as 9 stem-cells like 1 basal, 22 baso-luminal, and 23 luminal subtypes

CONCLUSION: By using immunohistochemical staining panel, TNBC can be differentiated into stem cells like basal, baso-luminal and luminal subtypes. Didifferentiation and EMT can produce heterogeneity in TNBC subtypes and this will affect in handling TNBC. Stemness in stem cells- like subtypes are resistant to therapy. Therefore, TNBC needs special attention in order to assist in more optimal handling.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Li, Z, Tognon CE, Godinho FJ. ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex. Cancer Cell. 2017; 12:542-58. https://doi.org/10.1016/j.ccr.2007.11.012 PMid:18068631 PMCid:PMC2175032

Morrison BJ, Schmidt CW, Lakhani SR, Brent A, Reynolds BA, Lopez JA. Breast cancer stem cells: implications for therapy of breast cancer. Breast Cancer Research. 2018; 10(4):210. https://doi.org/10.1186/bcr2111 PMid:18671830 PMCid:PMC2575525

Leung ELH, Fiscus RR, Tung JW. Non-small cell lung cancer cells expressing CD44 are enriched for stem celllike properties. PLoS ONE. 2010; 5(11). https://doi.org/10.1371/journal.pone.0014062

Fang X, Zheng P, Tang J, Liu Y. CD24: from A to Z. Cellular and Molecular Immunology. 2010; 7(2):100-3. https://doi.org/10.1038/cmi.2009.119 PMid:20154703 PMCid:PMC4001892

Viale G, Rotmensz N, Maisonneuve P, Bottiglieri L, Montagna E, Luini A, Veronesi P, et al. Invasive ductal carcinoma of the breast with the "triplenegative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat. 2009; 116:317-28. https://doi.org/10.1007/s10549-008-0206-z PMid:18839307

Bernardi MA, Logullo AF, Pasini FS, Nonogaki S, Blumke C, Soares F, Brentani MM. Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer. Oncology Reports. 2011; 27:28-38. PMid:21956537

Kyo S, Sakaguchi J, Ohno S. High Twist expression is involved in infiltrative endometrial cancer and affects patient survival. Hum Pathol. 2006; 37:431-8. https://doi.org/10.1016/j.humpath.2005.12.021 PMid:16564917

Singhai R, Patil VW, Jaiswal SR, Patil SD, Tayade MB, Patil AV. E-Cadherin as a diagnostic biomarker in breast cancer. N Am J Med Sci. 2011; 3(5):227-33. https://doi.org/10.4297/najms.2011.3227 PMid:22558599 PMCid:PMC3337742

Saidi RF, Remine SG, Jacobs MJ. Interferon receptor alpha/beta is associated with improved survival after adjuvant therapy in resected pancreatic cancer. HPB. 2007; 9:289-94. https://doi.org/10.1080/13651820701329241 PMid:18345307 PMCid:PMC2215399

Cheang MC, Chia SK, Voduc D. Ki-67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009; 101:736-50. https://doi.org/10.1093/jnci/djp082 PMid:19436038 PMCid:PMC2684553

Idowu MO, Kmieciak M, Dumur C. "CD44+/CD24−/low cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome." Human Pathology. 2012; 43(3):364-73. https://doi.org/10.1016/j.humpath.2011.05.005 PMid:21835433

Published

2019-02-26

How to Cite

1.
Tan B, Kanoko M, Tan G, Bachtiar A, Munir D. Dimensional Analysis of CD44High CD24Low and Ki67 in Triple Negative Breast Cancer. Open Access Maced J Med Sci [Internet]. 2019 Feb. 26 [cited 2024 Mar. 29];7(4):526-8. Available from: https://oamjms.eu/index.php/mjms/article/view/oamjms.2019.182

Issue

Section

A - Basic Science

Most read articles by the same author(s)

1 2 3 > >> 

Similar Articles

You may also start an advanced similarity search for this article.